ERR2208969
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- MITOTIC_SPINDLE+0.400
- MTORC1_SIGNALING+0.400
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- TGF_BETA_SIGNALING+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANGIOGENESIS+0.300
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- ADIPOGENESIS-0.200
- FATTY_ACID_METABOLISM-0.200
- KRAS_SIGNALING_DN-0.200
- NOTCH_SIGNALING-0.200
- PEROXISOME-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
- HEME_METABOLISM-0.100
- MYOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A1HS-01A-11R-A13Y-07 | — | — | 0.868 |
| 2 | SRR8943028 | — | — | 0.866 |
| 3 | ERR2208923 | — | — | 0.857 |
| 4 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.856 |
| 5 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.854 |
| 6 | SRR934852 | — | — | 0.852 |
| 7 | TCGA-CU-A0YN-01A-21R-A10U-07 | — | — | 0.847 |
| 8 | TCGA-XF-AAMW-01A-11R-A42T-07 | — | — | 0.843 |
| 9 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.837 |
| 10 | SRR934886 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |